| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.10.42 |
| P698 | PubMed publication ID | 20465390 |
| P2093 | author name string | Christine E Napier | |
| Karen L MacKenzie | |||
| Michelle F Maritz | |||
| Victoria W Wen | |||
| P2860 | cites work | Mammalian telomeres end in a large duplex loop | Q22009893 |
| A telomerase component is defective in the human disease dyskeratosis congenita | Q22010917 | ||
| Telomerase modulates Wnt signalling by association with target gene chromatin | Q24310084 | ||
| hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization | Q24310670 | ||
| Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT | Q24313396 | ||
| Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly | Q24313436 | ||
| X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions | Q24317067 | ||
| TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes | Q24318921 | ||
| A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis | Q24323178 | ||
| Extension of life-span by introduction of telomerase into normal human cells | Q24336088 | ||
| The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats | Q24339608 | ||
| A biomarker that identifies senescent human cells in culture and in aging skin in vivo | Q24562644 | ||
| Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10 | Q24597936 | ||
| Telomere shortening and apoptosis in telomerase-inhibited human tumor cells | Q24598974 | ||
| TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita | Q24655738 | ||
| Characterization of primitive hematopoietic cells from patients with dyskeratosis congenita | Q36591308 | ||
| Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death | Q36742412 | ||
| Telomerase immunity from bench to bedside: round one. | Q36745749 | ||
| Telomere terminal transferase activity from Euplotes crassus adds large numbers of TTTTGGGG repeats onto telomeric primers | Q36758147 | ||
| Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex | Q36934008 | ||
| Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity | Q36973681 | ||
| Physiological assembly and activity of human telomerase complexes | Q37022486 | ||
| TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. | Q37041915 | ||
| Telomerase and cancer therapeutics | Q37078833 | ||
| Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. | Q38291849 | ||
| Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells | Q38295184 | ||
| Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. | Q38329911 | ||
| Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma | Q38345219 | ||
| Inhibition of telomerase activity with hTERT antisense increases the effect of CDDP-induced apoptosis in myeloid leukemia | Q38363590 | ||
| The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. | Q39120582 | ||
| Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase. | Q39844637 | ||
| Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo | Q39986635 | ||
| Screening of telomerase inhibitors | Q39998035 | ||
| Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase | Q40174226 | ||
| Human telomerase reverse transcriptase protects hematopoietic progenitor TF-1 cells from death and quiescence induced by cytokine withdrawal | Q40284074 | ||
| Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer | Q40345507 | ||
| Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. | Q40357992 | ||
| Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma | Q40382781 | ||
| Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita | Q24680286 | ||
| Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential | Q24814196 | ||
| Specific Association of Human Telomerase Activity with Immortal Cells and Cancer | Q27860801 | ||
| Reconstitution of human telomerase activity in vitro | Q28116966 | ||
| The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes | Q28139460 | ||
| Creation of human tumour cells with defined genetic elements | Q28141602 | ||
| Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children | Q28141910 | ||
| The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita | Q28189076 | ||
| Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas | Q28258624 | ||
| Shelterin: the protein complex that shapes and safeguards human telomeres | Q28272546 | ||
| The RNA component of human telomerase | Q28288330 | ||
| Protein composition of catalytically active human telomerase from immortal cells | Q28295708 | ||
| Telomere dysfunction and evolution of intestinal carcinoma in mice and humans | Q28504673 | ||
| Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival | Q28573374 | ||
| Conditional telomerase induction causes proliferation of hair follicle stem cells | Q28591715 | ||
| Effects of telomerase and telomere length on epidermal stem cell behavior | Q28592564 | ||
| Origin of Concatemeric T7DNA | Q28639751 | ||
| A highly selective telomerase inhibitor limiting human cancer cell proliferation | Q29301431 | ||
| The serial cultivation of human diploid cell strains | Q29547356 | ||
| Telomeres shorten during ageing of human fibroblasts | Q29547357 | ||
| A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis | Q29614741 | ||
| Telomerase catalytic subunit homologs from fission yeast and human | Q29615387 | ||
| A DNA damage checkpoint response in telomere-initiated senescence | Q29615919 | ||
| A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes | Q29617061 | ||
| Essential role of mouse telomerase in highly proliferative organs | Q29620451 | ||
| Inhibition of telomerase by G-quartet DNA structures | Q30450395 | ||
| Development and aging of primitive hematopoietic stem cells in BALB/cBy mice | Q30700758 | ||
| Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro | Q30764160 | ||
| Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay | Q31880006 | ||
| Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals | Q32062889 | ||
| Genetic regulation of primitive hematopoietic stem cell senescence | Q33180235 | ||
| Telomere Length in Subpopulations of Human Hematopoietic Cells | Q33194487 | ||
| Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes | Q33226956 | ||
| A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis | Q33375057 | ||
| Comparing effects of mTR and mTERT deletion on gene expression and DNA damage response: a critical examination of telomere length maintenance-independent roles of telomerase | Q33566461 | ||
| Telomeres do D-loop-T-loop | Q33641397 | ||
| Epigenetic control of telomerase and modes of telomere maintenance in aging and abnormal systems | Q36071774 | ||
| The rate of telomere sequence loss in human leukocytes varies with age. | Q36093340 | ||
| Telomere diseases | Q36107376 | ||
| Inhibition of human telomerase by 2'-O-methyl-RNA | Q36312946 | ||
| Loss of proliferative capacity in immunohemopoietic stem cells caused by serial transplantation rather than aging | Q36340236 | ||
| Loss of stem cell repopulating ability upon transplantation. Effects of donor age, cell number, and transplantation procedure | Q36347180 | ||
| Long-term erythropoietic repopulating ability of old, young, and fetal stem cells | Q36347797 | ||
| Ontogeny-related changes in proliferative potential of human hematopoietic cells | Q36362285 | ||
| Telomere shortening accompanies increased cell cycle activity during serial transplantation of hematopoietic stem cells | Q36369240 | ||
| Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. | Q36375132 | ||
| Telomere length homeostasis | Q36495238 | ||
| Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts | Q36554262 | ||
| Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines | Q36556649 | ||
| Differentiation of immortal cells inhibits telomerase activity. | Q33670557 | ||
| In vivo telomere dynamics of human hematopoietic stem cells | Q33726870 | ||
| Telomere length and replicative aging in human vascular tissues | Q33763501 | ||
| The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. | Q33852211 | ||
| p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis | Q33862956 | ||
| Telomerase activity in normal and malignant hematopoietic cells | Q33883794 | ||
| Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice | Q33914498 | ||
| Telomerase activation by histone deacetylase inhibitor in normal cells | Q33940715 | ||
| Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors | Q33948004 | ||
| Preferential maintenance of critically short telomeres in mammalian cells heterozygous for mTert. | Q34019245 | ||
| Telomere reduction in human colorectal carcinoma and with ageing | Q34037761 | ||
| Dissociation of telomerase activity and telomere length maintenance in primitive human hematopoietic cells | Q34063522 | ||
| Dyskeratosis congenita in all its forms | Q34071682 | ||
| Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus | Q34084088 | ||
| Telomerase contributes to tumorigenesis by a telomere length-independent mechanism | Q34188701 | ||
| Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations | Q34264324 | ||
| Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells | Q34335191 | ||
| Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia | Q34409487 | ||
| Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure | Q34417578 | ||
| Telomerase inhibition, oligonucleotides, and clinical trials | Q34535686 | ||
| Telomerase as a universal tumor-associated antigen for cancer immunotherapy | Q34535727 | ||
| Telomeres and telomerase in hematologic neoplasia | Q34535734 | ||
| Recognition and elongation of telomeres by telomerase | Q34676361 | ||
| Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. | Q34724924 | ||
| The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena | Q34810908 | ||
| Telomere fusions caused by mutating the terminal region of telomeric DNA | Q35291052 | ||
| Telomeric DNA in normal and leukemic blood cells | Q35553065 | ||
| T-loops and the origin of telomeres | Q35741027 | ||
| hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors | Q35791425 | ||
| Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence | Q35849897 | ||
| Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. | Q35925269 | ||
| Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita | Q35989413 | ||
| The signals and pathways activating cellular senescence | Q36060167 | ||
| Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. | Q40499538 | ||
| Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition | Q40554439 | ||
| Telomerase is limiting the growth of acute myeloid leukemia cells. | Q40625633 | ||
| Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma | Q40635344 | ||
| Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy | Q40662526 | ||
| Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival | Q40667600 | ||
| The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation | Q40680048 | ||
| A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity | Q40737219 | ||
| Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes | Q40811313 | ||
| Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts | Q40812808 | ||
| Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. | Q40856900 | ||
| Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase | Q40890122 | ||
| Replicative senescence: implications for in vivo aging and tumor suppression | Q41003046 | ||
| Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening | Q41121125 | ||
| Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability | Q41429993 | ||
| Evidence for a critical telomere length in senescent human fibroblasts | Q41678139 | ||
| Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms | Q41874345 | ||
| Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow | Q42528725 | ||
| G-quadruplex preferentially forms at the very 3' end of vertebrate telomeric DNA | Q42576862 | ||
| In vivo accumulation of 8-hydroxy-2'-deoxyguanosine in DNA correlates with release of reactive oxygen species in Fanconi's anaemia families | Q42683112 | ||
| Karyotypic and phenotypic changes during in vitro aging of human endothelial cells | Q42804136 | ||
| Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex | Q43905645 | ||
| Efficient RNA interference (RNAi) in Mamallian Cells | Q43918566 | ||
| Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways | Q44549002 | ||
| Inhibition of Vertebrate Telomerases by the Triphosphate Derivatives of Some Biologically Active Nucleosides | Q44622318 | ||
| Introduction of human telomerase reverse transcriptase to normal human fibroblasts enhances DNA repair capacity | Q44836622 | ||
| Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation | Q44965351 | ||
| Effects of telomerase modulation in human hematopoietic progenitor cells | Q45041222 | ||
| Significant telomere shortening in childhood leukemia | Q45099372 | ||
| Establishing the incidence of myelodysplastic syndrome | Q45203093 | ||
| Human short-term repopulating cells have enhanced telomerase reverse transcriptase expression. | Q45861253 | ||
| In situ analyses of genome instability in breast cancer | Q46051522 | ||
| Sequence-specific DNA cleavage by Fe2+-mediated fenton reactions has possible biological implications | Q46085269 | ||
| Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy | Q46535481 | ||
| Patterns of occurrence of the leukaemias | Q46608622 | ||
| Telomere length in paroxysmal nocturnal hemoglobinuria correlates with clone size | Q47274641 | ||
| Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. | Q47775716 | ||
| Inhibition of human telomerase activity by peptide nucleic acids | Q47960865 | ||
| Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. | Q50910580 | ||
| Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. | Q52022148 | ||
| Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. | Q52191382 | ||
| Telomerase maintains telomere structure in normal human cells. | Q52551445 | ||
| Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. | Q52974538 | ||
| Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. | Q53387220 | ||
| Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. | Q53650886 | ||
| Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. | Q53851296 | ||
| A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. | Q53944952 | ||
| Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. | Q55470736 | ||
| Synthetic 2'-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. | Q55477504 | ||
| Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa | Q57219154 | ||
| Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage | Q58276515 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 769-789 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Targeting telomerase in hematologic malignancy | |
| P478 | volume | 6 |
Search more.